A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Number of participants on high dose Vitamin D with adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of a high dose of vitamin D (VD) in patients with cirrhosis. The investigator hypothesizes that high dose VD will be safe and well-tolerated in adults with cirrhosis, and will inhibit the inflammatory and proliferative events that cause progression of cirrhosis to hepatocellular carcinoma.
详细描述
This study will be done in two phases. The first phase is being done to find the highest dose of VD that can be tolerated, in other words taken without causing severe side effects. The second phase is a 6 month treatment with the dose determined to be safe in the first phase, to investigate general health benefits and the potential to reduce the development of Hepatocellular carcinoma (HCC), also known as liver cancer. Improvement of general health will be determined by interviews with patients, markers in the blood for response to VD, bone remodeling, inflammation, and evidence of HCC on routine imaging.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects between the ages of 18 and 75 with cirrhosis of any etiology followed at the Georgetown Transplant Institute, Washington, DC, will be offered entry into this study. The diagnosis of cirrhosis will be based on clinical, imaging or histological studies.
- •No evidence of HCC on entry imaging study ( if liver nodules are present, these should be classified as LIRADS 1-3 only).
- •Model for End Stage Liver Disease (MELD) score under 22 (a MELD score over 22 would predict a 3 month mortality rate of approximately 20%).
- •Not currently participating in another intervention study.
- •Not pregnant or lactating, and willing to use effective contraception during study period.
- •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- •Ability to provide written informed consent according to national/local regulations
排除标准
- •Any diagnosis of kidney stones
- •A diagnosis of granulomatous diseases (e.g., sarcoidosis), active chronic fungal or mycobacterial infections (e.g., tuberculosis, histoplasmosis, coccidioidomycosis, blastomycosis, berylliosis, or Wegener's granulomatosis) in the past 6 months
- •A diagnosis of hyperparathyroidism or other serious disturbance of calcium metabolism in the past 5 years
- •A diagnosis of severe kidney disease, e.g., chronic renal failure, in the past 6 months
- •A diagnosis of unexplained hypercalcemia in the past 6 months
- •Any diagnosis of osteoporosis with physician recommendation for treatment of low bone mass
- •A diagnosis of two or more low trauma fractures in the past 6 months
- •A diagnosis of a medical condition requiring treatment with VD (e.g., osteomalacia) in the past 6 months
研究组 & 干预措施
Dose VD 1
Vitamin D
干预措施: Vitamin D (Drug)
Dose VD 2
Vitamin D
干预措施: Vitamin D (Drug)
Dose VD 3
Vitamin D
干预措施: Vitamin D (Drug)
Dose VD 4
Vitamin D
干预措施: Vitamin D (Drug)
Dose VD 5
Vitamin D
干预措施: Vitamin D (Drug)
VD 6 Month Treatment
Vitamin D
干预措施: Vitamin D (Drug)
结局指标
主要结局
Number of participants on high dose Vitamin D with adverse events
时间窗: after 1 year
次要结局
- Changes in the expression of serum and imaging biomarkers(After 6 months on vitamin D regimen)